Overview

Luspatercept + Darbepoetin in MDS

Status:
NOT_YET_RECRUITING

Trial end date:
2030-05-01

Target enrollment:

Participant gender:

Summary

This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in SF3B1 wild type, lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.

Phase:

PHASE2

Details

Lead Sponsor:

Yale University

Collaborator:

Bristol-Myers Squibb

Treatments:

luspatercept